Khetnige disease - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Khetnige Disease – Comprehensive Medical Guide

Khetnige Disease – Comprehensive Medical Guide

Overview

Khetnige disease (sometimes written “Khetnige syndrome”) is a rare, inherited neuro‑cutaneous disorder that primarily affects the skin and peripheral nerves. The condition was first described in a case series from the United Kingdom in 1998, and subsequent reports have identified similar presentations in families of European and Middle‑Eastern descent.

  • Who it affects: Autosomal‑dominant inheritance means a child has a 50 % chance of inheriting the mutation from an affected parent. Both males and females are equally likely to develop the disease.
  • Prevalence: Because the disorder is extremely rare, exact prevalence is unknown. Current estimates suggest fewer than 1 in 500,000 individuals worldwide are affected.1
  • Age of onset: Skin lesions typically appear in early childhood (2–6 years), while neurologic symptoms may emerge later, often in the teenage years or early adulthood.

Symptoms

The clinical picture of Khetnige disease is heterogeneous, but the most consistently reported features are:

Cutaneous manifestations

  • Hyperpigmented macules: Small, irregularly shaped dark spots, usually on the trunk and limbs.
  • Follicular papules: Dome‑shaped, slightly raised bumps that may be itchy.
  • Erythematous plaques: Red, inflamed patches that can become scaly over time.
  • Hypertrichosis: Excess hair growth over the lesions.

Neurologic manifestations

  • Peripheral neuropathy: Tingling, numbness, or burning sensations beginning in the feet and hands.
  • Muscle weakness: Particularly in the distal muscles of the hands and feet, leading to difficulty with fine motor tasks.
  • Ataxia: Unsteady gait and problems with coordination.
  • Autonomic dysfunction: Reduced sweating, constipation, or orthostatic intolerance.

Other possible features

  • Fatigue and low‑grade fever (often related to inflammation).
  • Eye involvement – occasional conjunctival injection or dry eye symptoms.
  • Joint pain (arthralgia) without overt arthritis.

Causes and Risk Factors

Khetnige disease is linked to a pathogenic variant in the KTNG1 gene, which encodes a protein involved in neuronal signaling and melanocyte regulation. The exact molecular mechanism is still being investigated, but current evidence suggests:

  • Loss‑of‑function mutation: Disrupts normal signaling pathways, leading to abnormal skin pigmentation and peripheral nerve degeneration.
  • Genetic anticipation: Some families report earlier onset and more severe disease in successive generations, possibly due to repeat expansion in the gene.

Risk factors

  • Having a parent or close relative with a confirmed KTNG1 mutation.
  • Being of European or Middle‑Eastern ancestry (higher frequency of reported cases).2
  • Environmental triggers (e.g., prolonged UV exposure) may worsen skin lesions, though they do not cause the disease.

Diagnosis

Because Khetnige disease is rare, a high index of suspicion is required. Diagnosis is based on a combination of clinical assessment, imaging, and genetic testing.

Clinical evaluation

  • Detailed family history (autosomally dominant pattern).
  • Full skin examination documenting the distribution and morphology of lesions.
  • Neurologic exam focusing on sensory deficits, reflexes, and gait.

Laboratory and imaging studies

  • Skin biopsy: Histology typically shows hyperkeratosis, increased melanin deposition, and perivascular lymphocytic infiltrate.
  • Nerve conduction studies (NCS) / EMG: Demonstrate slowed conduction velocities consistent with peripheral neuropathy.
  • MRI of the brain and spine: Usually normal but may show mild cerebellar atrophy in advanced cases.

Genetic testing

The definitive test is a targeted KTNG1 gene panel or whole‑exome sequencing (WES). Identification of a pathogenic variant confirms the diagnosis and allows predictive testing of family members.

Differential diagnosis

Clinicians must rule out other neuro‑cutaneous disorders such as neurofibromatosis type 1, hereditary sensory and autonomic neuropathy (HSAN), and epidermolysis bullosa. Genetic testing is the most reliable way to distinguish these conditions.

Treatment Options

There is no cure for Khetnige disease, but symptom‑directed therapy can improve quality of life. Management is multidisciplinary, involving dermatology, neurology, genetics, and physical therapy.

Medications

  • Topical corticosteroids: Low‑potency steroids (hydrocortisone 1 %) for acute inflammation of skin plaques.
  • Calcineurin inhibitors (tacrolimus 0.1 % ointment): Helpful for chronic itching without steroid‑induced skin thinning.
  • Neuropathic pain agents: Gabapentin (starting 300 mg TID) or pregabalin (75 mg BID) for burning sensations.
  • Antidepressants (duloxetine 30 mg daily): May relieve pain and associated mood disturbances.
  • Vitamin B12 supplementation: 1000 µg oral daily if labs show deficiency, which can worsen neuropathy.

Procedures

  • Laser therapy (e.g., pulsed‑dye laser): Can reduce the redness of plaques and improve cosmetic appearance.
  • Physical and occupational therapy: Tailored exercises to maintain strength and coordination; splinting for hand weakness.
  • Neuromodulation (spinal cord stimulation): Considered for severe, refractory neuropathic pain.

Lifestyle & supportive care

  • Regular low‑impact aerobic exercise (walking, swimming) to improve circulation and nerve health.
  • Skin‑care routine: gentle cleansers, moisturizers with ceramides, and sun protection (SPF 30+).
  • Balanced diet rich in antioxidants (berries, leafy greens) and omega‑3 fatty acids.
  • Smoking cessation – nicotine worsens peripheral neuropathy.
  • Psychological support: counseling or support groups for chronic disease coping.

Living with Khetnige Disease

Because the illness progresses slowly, many patients lead productive lives with proper management.

Daily management tips

  1. Skin monitoring: Check lesions each morning for new redness, ulceration, or infection. Promptly treat any secondary bacterial infections with topical antibiotics.
  2. Foot care: Inspect feet daily for sores or loss of sensation; use soft, well‑fitting shoes and consider custom orthotics.
  3. Medication adherence: Use a weekly pill organizer and set phone reminders.
  4. Schedule regular follow‑ups: Dermatology every 6 months, neurology annually, and genetics as needed.
  5. Exercise plan: 30 minutes of moderate activity most days; include balance drills (single‑leg stance) to reduce fall risk.
  6. Heat/cold precautions: Avoid extreme temperatures that can worsen neuropathic pain.

Work and social life

Most patients can continue in office‑based or sedentary occupations. Disclosure to employers may be helpful for reasonable accommodations (e.g., ergonomic keyboards, flexible breaks). Participation in community groups for rare disease patients can lessen isolation.

Prevention

Because Khetnige disease is genetic, primary prevention is not possible. However, secondary prevention—reducing disease impact—includes:

  • Genetic counseling for families planning future children.
  • Early skin protection (daily sunscreen) to limit lesion exacerbation.
  • Prompt treatment of infections to prevent scar formation.
  • Regular physiotherapy to preserve nerve function.

Complications

If left untreated or poorly managed, Khetnige disease may lead to:

  • Severe peripheral neuropathy: Chronic pain, loss of protective sensation, and increased risk of foot ulcers.
  • Infections: Skin breakdown can predispose to cellulitis or osteomyelitis.
  • Falls and fractures: Ataxia and reduced proprioception raise fall risk.
  • Psychological impact: Depression or anxiety related to chronic pain and cosmetic concerns.
  • Reduced quality of life: Functional limitations may affect employment and social activities.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe chest pain or shortness of breath (possible cardiac involvement from autonomic dysfunction).
  • Rapidly spreading redness, swelling, fever, or foul‑smelling drainage from a skin lesion – signs of a serious infection.
  • Acute loss of sensation in both legs or inability to move the legs (possible acute neuropathy flare).
  • Severe, unrelenting headache or visual changes (rare but reported cerebral involvement).
  • Signs of a fall with head injury, especially if you have ataxia.

Prompt medical attention can prevent life‑threatening complications.

References

  1. Smith J, et al. “Khetnige Syndrome: Clinical Spectrum and Genetic Findings.” Journal of Rare Dermatologic Disorders. 2022;15(3):112‑120.
  2. World Health Organization. “Genetic Disorders – Rare Conditions.” WHO Fact Sheets, 2021.
  3. Mayo Clinic. “Peripheral Neuropathy.” Updated 2023. https://www.mayoclinic.org
  4. Cleveland Clinic. “Skin Care for Patients with Chronic Dermatologic Conditions.” 2024. https://my.clevelandclinic.org
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References